Company intelligence / Profile preview

Mitomics

Thunder Bay, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

Mitomics markets the Prostate Core Mitomic Test (PCMT), a mitochondrial DNA-based diagnostic with 84% sensitivity and 91% negative predictive value for detecting prostate cancer in biopsy tissue. Additional tests for breast cancer and endometriosis are in development.[1][2]

Therapeutic areas: OncologyWomen's Health
Industry: Molecular Diagnostics

Partnerships

Bostwick Laboratories

Beyond the preview

Go deeper on Mitomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitomics.

Explore the full profile